유방암 환자의 항암화학요법으로 인한 말초신경병증: 관련요인 및 건강 관련 삶의 질에 미치는 영향
Chemotherapy-induced Peripheral Neuropathy in Patients with Breast Cancer: Associated Factors and Impact on Health-Related Quality of Life
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to identify factors associated with the occurrence of chemotherapy-induced peripheral neuropathy(CIPN) and to study its impact on health-related quality of life (HRQoL) in patients with breast cancer. Methods: In total, 137 women with breast cancer who had undergone more than one cycle of chemotherapy were recruited for this descriptive study from the outpatient department of a university hospital in Incheon, Korea. Data were collected using a self-reported questionnaire, which included the European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 and EORTC QLQ-C30. Results: The mean CIPN score between patients was 13.57 on the sensory scale, 15.87 on the motor scale, and 25.06 on the autonomic scale. Of the studied socio-demographic, disease and treatment, and health behavior-related factors, only the chemotherapy regimen was significantly associated with CIPN (t = 2.50, p= .013). Taxane-based chemotherapy was significantly related to higher CIPN scores. Regression analyses revealed that CIPN was a factor that was significantly influential on HRQoL, adjusting for socio-demographic and clinical factors. Conclusion: This study suggests that oncology nurses need to be aware of the increased risk of CIPN in patients with breast cancer undergoing taxane-based chemotherapy. In addition, interventions for alleviating CIPN may be required to improve HRQoL among these patients.
Abstract
Purpose: This study aimed to identify factors associated with the occurrence of chemotherapy-induced peripheral neuropathy(CIPN) and to study its impact on health-related quality of life (HRQoL) in patients with breast cancer. Methods: In total, 137 women with breast cancer who had undergone more than one cycle of chemotherapy were recruited for this descriptive study from the outpatient department of a university hospital in Incheon, Korea. Data were collected using a self-reported questionnaire, which included the European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 and EORTC QLQ-C30. Results: The mean CIPN score between patients was 13.57 on the sensory scale, 15.87 on the motor scale, and 25.06 on the autonomic scale. Of the studied socio-demographic, disease and treatment, and health behavior-related factors, only the chemotherapy regimen was significantly associated with CIPN (t = 2.50, p= .013). Taxane-based chemotherapy was significantly related to higher CIPN scores. Regression analyses revealed that CIPN was a factor that was significantly influential on HRQoL, adjusting for socio-demographic and clinical factors. Conclusion: This study suggests that oncology nurses need to be aware of the increased risk of CIPN in patients with breast cancer undergoing taxane-based chemotherapy. In addition, interventions for alleviating CIPN may be required to improve HRQoL among these patients.
참고문헌 (28)
- "Breast cancer"[URL]
- "NCCN guidelines for treatment of breast cancer"[URL]
- Kim HJ, "Clinical subgroups of a psychoneurologic symptom cluster in women receiving treatment for breast cancer : a secondary analysis", Oncol Nurs Forum, 39, pp.E20~E30 (2012)
- Hsu HT, "Symptom cluster trajectories during chemotherapy in breast cancer outpatients", J Pain Symptom Manage, 53, pp.1017~1025 (2017)
- 김경덕, "항암화학요법을 받고 있는 유방암 환자의 증상 클러스터와 삶의 질", 성인간호학회지, 23(5), pp.434~445 (2011), 한국성인간호학회
- Wickham R, "Chemotherapy-induced peripheral neuropathy : a review and implications for oncology nursing practice", Clin J Oncol Nurs, 11, pp.361~376 (2007)
- Argyriou AA, "Chemotherapy-induced peripheral neurotoxicity(CIPN) : an update", Crit Rev Oncol Hematol, 82, pp.51~77 (2012)
- Cavaletti G, "Chemotherapy-induced peripheral neurotoxicity", Nat Rev Neurol, 6, pp.657~666 (2010)
- Greenlee H, "BMI, lifestyle factors and taxane-induced neuropathy in breast cancer patients: the pathways study", J Natl Cancer Inst, 109, pp.djw206~ (2016)
- Verstappen CCP, "Neurotoxic complications of chemotherapy in patients with cancer : clinical signs and optimal management", Drugs, 63, pp.1549~1563 (2003)
- Harlan LC, "Adjuvant therapy for breast cancer : practice patterns of community physicians", J Clin Oncol, 20, pp.1809~1817 (2002)
- "Basic information about breast cancer"[URL]
- Miltenburg NC, "Chemotherapy-induced neuropathy : a comprehensive survey", Cancer Treat Rev, 40, pp.872~882 (2014)
- Wilkes G, "Peripheral neuropathy related to chemotherapy", Semin Oncol Nurs, 23, pp.162~173 (2007)
- 곽미경(Kwak, Mi Kyong), "항암화학요법으로 인한 암환자의 말초신경병증 관련 특성과 삶의 질", Asian Oncology Nursing, 10(2), pp.231~239 (2010), 대한종양간호학회
- Tofthagen C, "Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin", Clin J Oncol Nurs, 15, pp.182~188 (2011)
- Kim MJ, "Influence of chemotherapy induced peripheral neuropathy(CIPN)symptom experience on activity interference in breast cancer patients : based on the theory of unpleasant symptoms", master, pp.2017
- 김혜영, "유방암 환자의 항암화학요법으로 인한 말초신경병증과 삶의 질", Asian Oncology Nursing, 13(4), pp.222~230 (2013), 대한종양간호학회
- Postma TJ, "The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy : the QLQ-CIPN20", Eur J Cancer, 41, pp.1135~1139 (2005)
- 김혜영, "Reliability and Validity of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to Assess Chemotherapy-induced Peripheral Neuropathy", Journal of Korean Academy of Nursing, 44(6), pp.735~742 (2014), 한국간호과학회
- Yun YH, "Validation of the Korean version of the EORTC QLQ-C30", Qual Life Res, 13, pp.863~868 (2004)
- Wolf S, "Chemotherapy-induced peripheral neuropathy : prevention and treatment strategies", Eur J Cancer, 44, pp.1507~1515 (2008)
- Simon NB, "The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice", Qual Life Res, 26, pp.2763~2772 (2017)
- Kaley TJ, "Therapy of chemotherapy-induced peripheral neuropathy", Br J Haematol, 145, pp.3~14 (2009)
- Windebank AJ, "Chemotherapy-induced neuropathy", J Peripher Nerv Syst, 13, pp.27~46 (2008)
- McCrary JM, "Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy", Support Care Cancer, 27, pp.3849~3857 (2019)
- Kleckner IR, "Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy : a multicenter, randomized controlled trial", Support Care Cancer, 26, pp.1019~1028 (2018)
- Duregon F, "Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment : a systematic review", Crit Rev Oncol Hematol, 121, pp.90~100 (2018)